Resverlogix Provides Research and Development Update
News Oct 06, 2015
Resverlogix Corp. has announced that the Resverlogix clinical and science teams, along with two members of the international clinical steering committee for the upcoming BETonMACE study, presented a Research and Development Update for RVX-208 "apabetalone" on September 25, 2015 in New York City.
Highlights from the presentation included an in depth analysis of the large unmet medical need in diabetes patients at high risk for secondary major adverse cardiovascular events ("MACE") presented by the chair of the BETonMACE clinical steering committee, Professor Kausik K. Ray, BSc , MBChB, MD, MPhil, FACC, FAHA, FESC, FRCP.
In addition, a breakdown of the unmet medical need in Chronic Kidney Disease and the therapeutic potential of apabetalone in this indication were presented by clinical steering committee member, Dr. Kamyar Kalantar-Zadeh, MD, MPH, PhD, FAAP, FACP, FASN, FAHA, FNKF.
Senior Vice President of Clinical Development, Dr. Mike Sweeney, MD detailed the final design of the BETonMACE clinical trial, and Vice President of Scientific Development, Dr. Ewelina Kulikowski, PhD highlighted novel biology and findings from ongoing mechanistic studies focused on cardiovascular risk pathways and apabetalone's potential in reducing MACE.
Kenneth Lebioda, Senior Vice President of Business and Corporate Development finished with a discussion of findings from primary market research focusing on primary care physician and payer perceptions of apabetalone.
New evidence published in the Cochrane Library provides high quality evidence that people who use a combination of nicotine replacement therapies (a patch plus a short acting form, such as gum or lozenge) are more likely to successfully quit smoking than people who use a single form of the medicine.READ MORE